Should bisphosphonates be used in premenopausal women?

Maturitas

Volumn 66, Issue 1, 2010, Pages 3-4

  Cohen, Adi ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

Bisphosphonates; Fracture; Osteoporosis; Premenopausal

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; STEROID; BONE DENSITY CONSERVATION AGENT;

BONE DENSITY; BONE MASS; CORTICOSTEROID INDUCED OSTEOPOROSIS; EDITORIAL; FEMALE; FRACTURE; HUMAN; HYPOCALCEMIA; NONHUMAN; NUTRITIONAL DEFICIENCY; OSTEOLYSIS; OSTEOPOROSIS; PES EQUINOVARUS; PREMENOPAUSE;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; OSTEOPOROSIS; PREMENOPAUSE;

EID: 77950862772     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.02.018     Document Type: Editorial

References (16)

1. Thompson P.W., Taylor J., and Dawson A. The annual incidence and seasonal variation of fractures of the distal radius in men and women over 25 years in Dorset, UK. Injury 35 5 (2004) 462-466
2. Wu F., Mason B., Horne A., et al. Fractures between the ages of 20 and 50 years increase women's risk of subsequent fractures. Arch Intern Med 162 1 (2002) 33-36
3. Hosmer W.D., Genant H.K., and Browner W.S. Fractures before menopause: a red flag for physicians. Osteoporos Int 13 4 (2002) 337-341
4. Lewiecki E.M., Kendler D.L., Kiebzak G.M., et al. Special report on the official positions of the International Society for Clinical Densitometry. Osteoporos Int 15 10 (2004) 779-784
5. Lewiecki E.M. Premenopausal bone health assessment. Curr Rheumatol Rep 7 1 (2005) 46-52
6. Khosla S., Lufkin E.G., Hodgson S.F., Fitzpatrick L.A., and Melton III L.J. Epidemiology and clinical features of osteoporosis in young individuals. Bone 15 5 (1994) 551-555
7. Cohen A., Fleischer J., Freeby M.J., McMahon D.J., Irani D., and Shane E. Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center. J Womens Health (Larchmt) 18 1 (2009) 79-84
8. Peris P., Guanabens N., Martinez de Osaba M.J., et al. Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women. Semin Arthritis Rheum 32 1 (2002) 64-70
9. Cohen A., Liu X.S., Stein E.M., et al. Bone microarchitecture and stiffness in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 94 11 (2009) 4351-4360
10. Peris P., Monegal A., Martinez M.A., Moll C., Pons F., and Guanabens N. Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis. Clin Rheumatol 26 6 (2007) 958-961
11. Minsker D.H., Manson J.M., and Peter C.P. Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 121 2 (1993) 217-223
12. Munns C.F., Rauch F., Ward L., and Glorieux F.H. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19 10 (2004) 1742-1745
13. Levy S., Fayez I., Taguchi N., et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44 3 (2009) 428-430
14. Ornoy A., Wajnberg R., and Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 22 4 (2006) 578-579
15. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 10 (2007) 1479-1491
16. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., and Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90 3 (2005) 1294-1301